On August 24, 2026, Context Therapeutics is trading at $0.47, down -5.08% (5% down), with no confirmed company-specific catalyst identified.
- The latest investor-relations release was August 5, covering second-quarter results and pipeline progress; no newer material announcement appears available.
- Broader markets are modestly mixed, but the move is not clearly attributable to market-wide weakness. Recheck for delayed filings or news.